Gilead Sciences is an American biotechnology company with a distinguished product pipe line that, in recent years, has enjoyed high revenue, earnings-per-share, and net income growth.
In Q3 2014, Gilead grew year-over-year in a multitude of ways domestically and internationally; it also announced new research accomplishments, and maintained positive – if slightly slower – full-year guidance.
While some analysts believe Gilead’s growth will come to an end because of technicals and inherent risk, fundamental analysis indicates that Gilead will keep thriving.
I Know First’s algorithm predicts a bullish forecast for GILD in the 1-month and 3-month time frames.
About Gilead Sciences: Gilead Sciences (NASDAQ: GILD) is an American biotechnology company that is involved in drug discovery, development, and commercialization. Founded in 1987 in Foster City, California, Gilead has since expanded to develop operations in the North and South Americas, Europe, and the Asia-Pacific region. Having made twelve or so acquisitions, minimally, since 1999, Gilead has made itself a biotech giant in recent years. At present, the company generates approximately $11.3 billion in revenue, boasts an innovative and diverse product pipeline focusing on HIV, hepatitis B, influenza, HCV, cardiovascular, and respiratory disorders, and has experienced highly impressive earnings growth. It has been labelled one of the fastest growing companies in America by Fortune, one of America's top companies to work for by Forbes, and its acquisition of Pharmasset has been hailed as "one of the best pharma acquisitions ever" by the latter publication. Despite the fact that Gilead is evidently doing quite well, therefore, and despite relatively strong Q3 results on the company's part, certain analysts have put forward concerns surrounding Gilead's ability to grow in the future. As such, an examination of Gilead-related fundamentals is in order!
This algorthmic forecast is part of the "World Indices" package, as one of I Know First's quantitative investment solutions. We determine our world indices picks by screening our database daily using our advanced algorithm. The full World Indexes Package includes a daily forecast for a total of 20 indices with bullish and bearish signals:
top ten world indexes to long
top ten world indexes to short
Recommended Positions: Long Forecast Length:1 months (10/30/14 - 11/30/14) I Know First Average: 4.63%Get the "World Indices" Package.
The stocks selected here are the top performing aggressive stocks from I Know First: Daily Market Forecast’s November 24th 2014. The Stock Forecast titled Quant Trading:26.98% Average Return in 1 Year. This forecast is part of the "Risk-Conscious" package, as one of I Know First's quantitative investment solutions. The "I Know First Average" return was 26.98% versus a S&P500's return of 14.66% over the same time period. Learn how to read the predictions: Instructions Learn how to strategize with the forecast: Algorithmic Trading StrategiesPlease note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.
This Best Tech Stocks forecast is designed for investors and analysts who need predictions of the best performing stocks for the whole Technology Industry. It includes 20 stocks with bullish and bearish signals and indicates the best tech stocks to buy:
Top 10 tech stocks for the long position
Top 10 tech stocks for the short position
Package Name: Tech Stocks Recommended Positions: Long Forecast Length: 3 months (18/08/13 – 18/10/14) I Know First Average: 13.38% Get the “Top Tech Stocks” Package.
The stocks selected here are the top performing tech stocks from I Know First: Daily Market Forecast’s November 15th 2014 Stock Forecast titled Best Tech Stocks Based On Algorithm: Tech Stocks To Buy. This forecast is part of the Tech Stocks Package. The “I Know First Average” return was 15.27% versus the S&P 500’s return of 8.63% over the same time period.
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
company with a distinguished product pipe line that, in recent years, has enjoyed high revenue, earnings-per-share, and net income growth.
